# Suzhou Infinory Pharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/suzhou-infinory-pharmaceuticals

- Industry: Pharmaceuticals
- Headquarters: Suzhou, China
- Website: www.in-finory.com
- Latest round: Series A (Mar 11, 2024)
- Investors on record: 1

## About

Based in Suzhou, China, and established in 2020, Suzhou Infinory Pharmaceuticals, LLC is a biopharmaceutical company primarily engaged in the development of oncolytic virus drug. The company was founded by Yinghui Huang, a tenured professor at the Torrey Pines Molecular Institute in California, United States. In August 2023, the company's oncolytic virus injection, YH01, received implicit approval for clinical trials from the National Medical Products Administration (NMPA).

In March 2024, the company closed a series of A1 funding from new investor Sunbow Capital.

Suzhou Infinory Pharmaceuticals, LLC is committed to the oncolytic virus design, construction, verification, process development, and large-scale production. The company's core products include YH01, a drug targeting triple-negative breast cancer (TNBC) and other four product pipelines. The company also developed an OCDP ™ (Oncolytic Core Design Platform) technology platform that has developed more than ten oncolytic viruses.

The company will use the series A1 funds for the Phase I clinical study of the oncolytic virus product YH01.

## Funding rounds

- Series A, Mar 11, 2024 — Sunbow Capital

## Investors

- Sunbow Capital (https://capitalatlas.ai/funds/sunbow-capital) — Series A